EFS from randomization
Fig. 3 · Panel A
Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Mariano Provencio, Mark M Awad, Jonathan D Spicer, Annelies Janssens, Fedor Moiseyenko, Yang Gao, Yasutaka Watanabe, Aurelia Alexandru, Florian Guisier, Nikolaj Frost, Fabio Franke, T Jeroen Nicolaas Hiltermann, Jie He, Fumihiro Tanaka, Shun Lu, Cinthya Coronado Erdmann, Padma Sathyanarayana, Phuong Tran, Vipul Devas, Tina Cascone
Nat Cancer 7(1) 169-181
Individuals with non-small-cell lung cancer (NSCLC) with metastases to the ipsilateral mediastinum or subcarinal lymph nodes (N2 disease) have poor long-term survival. This exploratory analysis from the randomized phase 3 CheckMate 77T study assessed clinical outcomes by nodal status in individuals with stage III NSCLC who received neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab (nivolumab) versus neoadjuvant chemotherapy followed by surgery and adjuvant placebo (placebo). Here we show that among patients with N2 disease, nivolumab versus placebo improved event-free survival (1-year rate, 70% versus 45%; hazard ratio, 0.46 (95% confidence interval, 0.30-0.70)) and pathological complete response rate (22.0% versus 5.6%); 77% versus 73% had definitive surgery, of whom 84% versus 74% received a simple lobectomy. Furthermore, nivolumab improved outcomes versus placebo in patients with multistation N2 NSCLC (1-year event-free survival rate: 71% versus 46%; hazard ratio, 0.43 (0.21-0.88); pathological complete response rate, 29.0% versus 2.7%). In the N2 subgroup with definitive surgery, 67% and 59% of patients had nodal downstaging after surgery (57% versus 44% downstaged to node-negative disease). Median EFS in randomized patients with stage III non-N2 NSCLC was not reached with nivolumab and 17.0 months with placebo (1-year EFS rate, 74% versus 62%; hazard ratio, 0.60 (0.33-1.08)). No new safety signals were identified. These findings support perioperative nivolumab plus neoadjuvant chemotherapy as an efficacious treatment for stage III N2 disease and suggest that N2 status may not predict poor prognosis in resectable NSCLC treated with perioperative immunotherapy. ClinicalTrials.gov identifier: NCT04025879 .
7 个 Figure · 30 个 KM 面板
Fig. 3. EFS in patients with stage III NSCLC by N2 or non-N2 status. a – d , EFS from randomization in patients with N2 NSCLC ( a ), randomization in patients with non-N2 NSCLC ( b ), definitive surgery in patients with N2 NSCLC ( c ) and definitive surgery in patients with non-N2 NSCLC ( d ). Superscript letters ‘a’–‘d’ indicate the following 95% CIs: a, 58–78; b, 34–55; c, 60–84; d, 48–74. The HRs and the two-sided 95% CIs for comparisons of EFS between the treatment arms were estimated using an unstratified Cox proportional hazards model using the randomized arm as a single covariate. EFS rates at 1 year were estimated using Kaplan–Meier estimates on the EFS curve for each randomized arm. Source data
Fig. 3 · Panel A
Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel B
Panel B 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel C
Panel C 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel D
Panel D 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4. EFS from definitive surgery in patients with stage III N2 or non-N2 NSCLC by pCR status. a – d , EFS from surgery in patients with N2 NSCLC by pCR status ( a ), patients with non-N2 NSCLC by pCR status ( b ), patients with N2 NSCLC without pCR who received at least one dose of adjuvant treatment ( c ) and patients with non-N2 NSCLC without pCR who received at least one dose of adjuvant treatment ( d ). The superscript letter ‘a’ indicates that EFS from surgery included only patients with definitive surgery and with pCR status available. The ‘Without pCR’ subgroup included patients with pCR negatively assessed. The superscript letter ‘b’ indicates that HRs were not calculated for subgroups with less than ten responders in either treatment arm. The HRs and the two-sided 95% CIs for comparisons of EFS between the treatment arms were estimated using an unstratified Cox proportional hazards model using the randomized arm as a single covariate; NC, not calculated. Source data
Fig. 4 · Panel A
Panel A 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel B
Panel B 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel C
Panel C 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel D
Panel D 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 5. EFS from randomization in patients with stage III N2 or non-N2 NSCLC by number of adjuvant treatment doses. a – d , EFS from randomization in patients with N2 NSCLC with six or fewer doses of adjuvant treatment ( a ), patients with N2 NSCLC with more than six doses of adjuvant treatment ( b ), patients with non-N2 NSCLC with six or fewer doses of adjuvant treatment ( c ) and patients with non-N2 NSCLC with more than six doses of adjuvant treatment ( d ). The superscript letter ‘a’ indicates that HRs were not calculated for subgroups with less than ten patients with events. Superscript letters ‘b’ and ‘c’ indicate the following 95% CIs: b, 44–89; c, 10–59. Superscript letter ‘d’ indicates that in the nivolumab arm, 28 patients received the maximum 13 doses of adjuvant treatment, and 13 patients received 7–12 doses; in the placebo arm, 23 patients received 13 doses of adjuvant treatment and 18 patients received 7–12 doses. Superscript letters ‘e’–‘h’ indicate the following 95% CIs: e, 79–98; f, 57–84; g, 33–98; h, NR–NR. Superscript letter ‘i’ indicates that in the nivolumab arm, 22 patients received the maximum 13 doses of adjuvant treatment, and 4 patients received 7–12 doses; in the placebo arm, 24 patients received 13 doses of adjuvant treatment, and 9 patients received 7–12 doses. Superscript letters ‘j’ and ‘k’ indicate the following 95% CIs: j, 73–98; k, 74–97. The HRs and two-sided 95% CIs for comparisons of EFS between the treatment arms were estimated using an unstratified Cox proportional hazards model using the randomized arm as a single covariate. EFS rates at 1 year were estimated using Kaplan–Meier estimates on the EFS curve for each randomized arm. Source data
Fig. 5 · Panel A
Panel A 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 5 · Panel B
Panel B 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 5 · Panel C
Panel C 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 5 · Panel D
Panel D 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 3. EFS in patients with stage III N2 NSCLC by N2 station. EFS from ( a ) randomization in patients with single-station N2 NSCLC, ( b ) randomization in patients with multi-station N2 NSCLC, ( c ) definitive surgery in patients with single-station N2 NSCLC, and ( d ) definitive surgery in patients with multi-station N2 NSCLC. a The N2 subcategory was not reported in 1 patient in the nivolumab arm. b–e 95% CI: b 54–79; c 30–58; d 50–84; e 28–62. The HRs and the two-sided 95% CIs for comparisons of EFS between the treatment arms were estimated using an unstratified Cox proportional hazards model using the randomized arm as a single covariate. EFS rates at 1 year were estimated using Kaplan-Meier estimates on the EFS curve for each randomized arm. CI, confidence interval; EFS, event-free survival; HR, hazard ratio; NR, not reached; NSCLC, non-small cell lung cancer. Source data
Extended Data Fig. 3 · Panel A
Panel A 是同一 Extended Data Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 3 · Panel B
Panel B 是同一 Extended Data Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 3 · Panel C
Panel C 是同一 Extended Data Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 3 · Panel D
Panel D 是同一 Extended Data Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 4. EFS in patients with stage III N2 and non-N2 NSCLC with or without pCR. EFS from ( a ) randomization in patients with N2 NSCLC, ( b ) randomization in patients with non-N2 NSCLC, ( c ) randomization in patients with single-station N2 NSCLC, ( d ) randomization in patients with multi-station N2 NSCLC, ( e ) definitive surgery in patients with single-station N2 NSCLC, and ( f ) definitive surgery in patients with multi-station N2 NSCLC. a EFS from randomization included all randomized patients. The “Without pCR” subgroup included patients with pCR negatively assessed, patients without definitive surgery, and patients with definitive surgery but without pCR status available. b HRs were NC for subgroups with <10 responders in either treatment arm. c–j 95% CI: c 100–100; d 100–100; e 47–71; f 30–52; g 100–100; h 57–99; i 50–80; j 45–72. k The N2 subcategory was not reported in 1 patient in the nivolumab arm. l–s 95% CI: l 100–100; m 100–100; n 45–73; o 24–53; p 100–100; q 100–100; r 32–76; s 27–60. t EFS from surgery included only patients with definitive surgery and with pCR status available. The “Without pCR” subgroup included patients with pCR negatively assessed. The HRs and the two-sided 95% CIs for comparisons of EFS between the treatment arms were estimated using an unstratified Cox proportional hazards model using the randomized arm as a single covariate. EFS rates at 1 year were estimated using Kaplan-Meier estimates on the EFS curve for each randomized arm. CI, confidence interval; EFS, event-free survival; HR, hazard ratio; NC, not calculated; NR, not reached; NSCLC, non-small cell lung cancer; pCR, pathological complete response. Source data
Extended Data Fig. 4 · Panel A
Panel A 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 4 · Panel B
Panel B 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 4 · Panel C
Panel C 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 4 · Panel D
Panel D 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 4 · Panel E
Panel E 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 4 · Panel F
Panel F 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 5. EFS in patients with stage III N2 or non-N2 NSCLC by adjuvant treatment status. EFS from randomization in ( a ) patients with N2 NSCLC with at least one dose of adjuvant treatment, ( b ) patients with non-N2 NSCLC with at least one dose of adjuvant treatment, ( c ) patients with N2 NSCLC without adjuvant treatment, and ( d ) patients with non-N2 NSCLC without adjuvant treatment. a,b 95% CI: a 76–94; b 50–75. c HRs were NC for subgroups with <10 patients with events. d–i 95% CI: d 74–97; e 63–89; f 30–84; g NR–NR; h 21–81; i 5–75. The HRs and the two-sided 95% CIs for comparisons of EFS between the treatment arms were estimated using an unstratified Cox proportional hazards model using the randomized arm as a single covariate. EFS rates at 1 year were estimated using Kaplan-Meier estimates on the EFS curve for each randomized arm. CI, confidence interval; EFS, event-free survival; HR, hazard ratio; NC, not calculated; NR, not reached; NSCLC, non-small cell lung cancer. Source data
Extended Data Fig. 5 · Panel A
Panel A 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 5 · Panel B
Panel B 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 5 · Panel C
Panel C 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 5 · Panel D
Panel D 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 6. EFS from definitive surgery in patients with stage III N2 or non-N2 NSCLC by number of adjuvant treatment doses. EFS from surgery in ( a ) patients with N2 NSCLC with ≤6 doses of adjuvant treatment, ( b ) patients with N2 NSCLC with >6 doses of adjuvant treatment, ( c ) patients with non-N2 NSCLC with ≤6 doses of adjuvant treatment, and ( d ) patients with non-N2 NSCLC with >6 doses of adjuvant treatment. a HRs were NC for subgroups with <10 responders in either treatment arm. b In the nivolumab arm, 28 patients received the maximum 13 doses of adjuvant treatment and 13 patients received 7–12 doses; in the placebo arm, 23 patients received 13 doses of adjuvant treatment and 18 patients received 7–12 doses. c In the nivolumab arm, 22 patients received the maximum 13 doses of adjuvant treatment and 4 patients received 7–12 doses; in the placebo arm, 24 patients received 13 doses of adjuvant treatment and 9 patients received 7–12 doses. The HRs and the two-sided 95% CIs for comparisons of EFS between the treatment arms were estimated using an unstratified Cox proportional hazards model using the randomized arm as a single covariate. CI, confidence interval; EFS, event-free survival; HR, hazard ratio; NC, not calculated; NR, not reached; NSCLC, non-small cell lung cancer. Source data
Extended Data Fig. 6 · Panel A
Panel A 是同一 Extended Data Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 6 · Panel B
Panel B 是同一 Extended Data Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 6 · Panel C
Panel C 是同一 Extended Data Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 6 · Panel D
Panel D 是同一 Extended Data Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。